BioSpace News Archive

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced that it will present a company overview at the Aegis Capital Corp. Virtual Conference on February 23rd at 9:30am ET.

QuantuMDx Group Limited (“QuantuMDx”), today announces that its rapid PCR SARS-CoV-2 test, with the multiplex Q-POC platform, has been approved for continued sales in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”).

Sen-Jam Pharmaceutical, a nimble innovative startup revolutionizing inflammation out of New York, is partnering with researchers from Duke University School of Medicine (Durham, NC, USA) and Duke-NUS Medical School (Singapore) to find safe and effective oral treatments for the COVID-19 global pandemic.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the Cowen 42nd Annual Health Care Conference.

Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that it has amended its loan and security agreement with Oxford Finance LLC.

Viewpoint Molecular Targeting, Inc. announced today the appointment of Thijs Spoor, MBA as its Chief Executive Officer.

SanaraMedTech Inc. (“Sanara” or the “Company”) (NASDAQ: SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today certain unaudited preliminary results for the fourth quarter and full year 2021.

Cerveau Technologies, Inc. (Cerveau) and Nihon Medi-Physics (NMP), a leading company for radiopharmaceuticals in Japan, today announced that they signed a manufacturing service agreement, in which Cerveau grants NMP the right to manufacture [18F]MK-6240, a next generation investigational Positron Emission Tomography (PET) imaging agent.

Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical-stage biotechnology company developing the next generation of therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the start of efficacy animal studies with INTASYL-based antiviral compounds against SARS-CoV-2 infection, the virus that causes COVID-19.